Citalomine 10 Tablet is a form of antidepressant categorized under the selective serotonin reuptake inhibitor (SSRI) class of medications. It is primarily prescribed for the treatment of depression, effectively aiding in enhancing mood and preventing the occurrence of new depressive episodes. Additionally, this medication is utilized for managing panic disorder symptoms.

When it comes to administration, Citalomine 10 Tablet can be consumed with or without food as per the doctor's instructions. The appropriate dosage and frequency are determined by the healthcare provider to ensure optimal control over the symptoms. It is common for doctors to initiate treatment with a lower dose and then gradually adjust it. Patients are advised not to alter the dosage or discontinue the medication without consulting the doctor, even if they start feeling better. Abrupt changes may exacerbate the condition or lead to unpleasant withdrawal symptoms such as anxiety, restlessness, palpitations, dizziness, or sleep disturbances.

For maximum efficacy, it is recommended to take this medication consistently at the same time every day. If experiencing insomnia, doctors may suggest taking it in the morning. Patients may need to wait a few weeks before noticing improvements, and should promptly inform their doctor if there is no enhancement even after 4 weeks of therapy.

Potential side effects associated with Citalomine 10 Tablet include nausea, vomiting, fatigue, dry mouth, increased sweating, insomnia, reduced sexual drive, delayed ejaculation, erectile dysfunction, and some individuals may feel drowsy after ingestion. It is crucial to notify the doctor immediately if there is a sudden worsening of mood or any thoughts related to self-harm.

Before commencing treatment with Citalomine 10 Tablet, individuals should disclose to their healthcare provider if they have epilepsy, diabetes, liver or kidney disorders, any cardiac issues, or are currently using MAO inhibitors for depression. These conditions could influence the treatment outcomes, hence sharing comprehensive information about ongoing medications is essential to ensure safety during therapy.